Capital injection to accelerate M&A, AI-led operations, and expansion across Southeast Asia and the Middle East.

SINGAPORE, Sept. 2, 2025 /PRNewswire/ — Nuffield Holdings is pleased to announce the appointment of Mr Liu Song and Ms Zhang Na as new shareholders, marking a pivotal moment in the Group’s regional growth strategy. This investment brings in both capital and strategic insight, enabling Nuffield to accelerate mergers and acquisitions, scale operations, and enhance its leadership in Southeast Asia’s healthcare sector.

Experienced and Visionary Partners

Mr Liu Song is the Founder and CEO of In Group Holdings Pte Ltd and Kamall International Pte Ltd. With over a decade of experience in sectors including real estate, mining, financial services, trade, and healthcare, his leadership has helped shape cross-border enterprises across Asia. His investment holding company, headquartered in Singapore, plays an active role in advancing sustainable and technology-driven ventures.

Ms Zhang Na has extensive experience supporting ultra-high-net-worth individuals in establishing family offices and making investments in Singapore, successfully helping these entrepreneurs anchor their presence in the country. As Founder of Sing Wang Da Consultancy Pte. Ltd, she brings valuable regional insight and capital markets expertise.

Accelerating Growth and Expansion

“We are delighted to welcome both Mr Liu Song and Ms Zhang Na as strategic partners,” said Dr Samintharaj Kumar, CEO of Nuffield Holdings. “Their commitment to long-term value creation, combined with this new capital injection, gives us the momentum to fast-track our acquisition pipeline and strengthen our footprint as a leading healthcare and dental platform across Southeast Asia and the Middle East.”

Looking Ahead: Building the Region’s Foremost AI-Enabled Dental Support Organisation (DSO)

Nuffield Holdings is a leading healthcare group headquartered in Singapore with operations across Southeast Asia and the Middle East and is evolving into the region’s largest AI-enabled Dental Support Organisation (DSO), embedding Artificial Intelligence into diagnostics, treatment planning, operations, and patient care.

Recognised for its consistent performance, Nuffield Holdings has been listed among Singapore’s fastest-growing companies by Statista since 2019. It was named one of the “High-Growth Companies Asia-Pacific 2023” by the Financial Times and is a 2024 Enterprise 50 (E50) Award winner—highlighting its excellence in growth, innovation, and leadership.

Are You Building the Next Big Thing in Healthcare or Dentistry?

As part of its next growth phase, Nuffield Holdings is inviting investment pitches from ambitious entrepreneurs and healthcare innovators in dental and medical clinics, HealthTech startups, and platform technologies that align with its mission to scale patient-first, tech-enabled care across the region.

We are interested in:

• Clinics seeking growth capital or considering an exit
• Startups focused on AI, diagnostics, imaging, or patient engagement
• Technology providers with solutions for scaling operations

Nuffield offers more than funding—it offers partnership, infrastructure, and proven operational experience.

Have something exciting to share?

Entrepreneurs and healthcare innovators are invited to collaborate with Nuffield Holdings. Submit proposals to md@nuffieldholdings.com.sg

BEIJING, Sept. 2, 2025 /PRNewswire/ — This year, we observe the 80th anniversary of the victory in the Chinese People’s War of Resistance Against Japanese Aggression–a pivotal part of the World Anti-Fascist War. 

China’s contribution to the Allied victory was bolstered by extensive international support. As we commemorate this milestone in 2025, we are called to remember history, honor the heroes who fell, cherish peace and strive for a more promising future.

An ancient Chinese saying goes, “To understand the present, study history; to foresee the future, look to the past.” It comes from the Guanzi, an ancient Chinese text attributed to Guan Zhong, a prominent statesman and philosopher during the Spring and Autumn Period (770-476 B.C.). The sentence intends to convey that when confused by current affairs, look to history for answers; when uncertain of the future, seek guidance from the past.

On December 13, 2014, President Xi Jinping quoted the classic line in his address at the national memorial ceremony for the victims of the winter 1937-38 Nanjing Massacre, during which invading Japanese forces killed approximately 300,000 Chinese civilians and unarmed soldiers in Nanjing, then capital of China. He noted that the hardships of war suffered following the start of China’s modern era, which began with its defeat in the Opium War of 1840, have given the Chinese people a deeper appreciation for peace. He firmly rejected the law of the jungle and militarism as paths to coexistence, asserting instead that peace and cooperation are the enduring drivers of human progress.

From the September 18 Incident in 1931, or the start of imperial Japan’s invasion of China, to the full-scale war ignited by the July 7 Incident in 1937, and finally to Japan’s unconditional surrender in 1945, the Chinese people waged a fearless 14-year struggle. They sustained catastrophic losses, with over 35 million military and civilian casualties, before securing a great victory. Through tremendous national sacrifice, China established itself as a major Eastern theater of the World Anti-Fascist War and contributed immensely to its victory.

At the same time, the Chinese people will forever cherish the invaluable support extended by countries, peoples and organizations across the globe that stand for peace and justice. The American “Flying Tigers,” all volunteer pilots, braved dangerous conditions to open and secure the Hump air route over the Himalayas, ensuring the continuous transport of essential strategic supplies to China. Canadian doctor Norman Bethune and Indian doctor Dwarkanath Kotnis came to China to save lives. German businessman John Rabe and Danish national Bernhard Sindberg, a supervisor at a cement plant on the outskirts of Nanjing, protected Chinese refugees during the Nanjing Massacre. British professor Michael Lindsay and European journalist Hans Shippe courageously told the world about China’s resistance.

The victory in the War of Resistance Against Japanese Aggression was a triumph achieved by the Chinese people fighting shoulder to shoulder with other Allied nations and peace-loving people across the globe. History has proven that justice will always defeat evil and peace will ultimately prevail over war. By safeguarding the truth of history and cherishing the fruits of peace, we ensure that justice endures and peace prevails for generations to come.

Today, facing changes unseen in a century and a global landscape entangled in turbulence and transformation, looking back at history in the spirit of upholding peace, development and win-win cooperation is highly relevant. The Chinese people will stand together with people around the world to firmly defend the victorious outcomes of the World Anti-Fascist War. All should be committed to safeguarding the international system centered on the UN and the international order based on international law. Together, we will tirelessly work toward building a community with a shared future for humanity and continue contributing to the noble cause of global peace and development.

https://youtu.be/KU6A5nSTH4w 

Comments to lanxinzhen@cicgamericas.com

TikTok:

https://www.tiktok.com/@cachinachic/video/7545309158824742175?is_from_webapp=1&sender_device=pc&web_id=7227134149436605995

X:

https://x.com/BeijingReview/status/1962699660016975964

Facebook:

https://www.facebook.com/reel/1328935455285311/

Weibo:

https://weibo.com/1719349955/Q2FLwstS0

Website:

http://www.bjreview.com/Multimedia/Video/Wisdom_Without_Borders/202509/t20250902_800413624.html

STOCKHOLM, Sept. 2, 2025 /PRNewswire/ — Tactical communications expert INVISIO is announcing a brand-new headset offering unlimited versatility in the field, with zero compromise to sound quality, hearing protection and situational awareness. The new headset is suited for both dismounted and mounted operations.

This means customers and end-users can now rely on one headset to serve their needs across a range of environments from training to missions, dismounted and mounted. The versatility of the T30 is a groundbreaking development in tactical communications, as it removes the necessity for different headsets for different situations and reduces the need for additional equipment, training and costs.

Zero compromise, just tactical excellence

T30 leverages INVISIO’s expertise in this field, delivering market-leading hearing protection of 30 dB SNR / 33 dB NRS_A20 combining passive hearing protection with active noise reduction. The active noise reduction contributes to increased protection in low frequency noise environments, often associated with mounted situations. This allows users to spend more time in vehicles and reduces potential fatigue. The T30 also provides a unique implementation of active noise reduction, where noise reduction is active while full situational awareness is maintained, enabling maximum protection in all situations. Due to an upgraded acoustic design, the T30 provides best-in-class sound localization down to 9 degrees.

T30 offers double hearing protection (38 dB SNR / 39 dB NRS_A20) with optimized situational awareness. In double hearing protection mode, hear-through audio is fitted to match an acoustic filter in the in-ear plug, ensuring the user gets full double hearing protection whilst still gaining optimized situational awareness.

The T30 also provides headset embedded INVISIO audio, delivering unrivalled sound quality and Automatic RX Volume Adjustment, adjusting radio volume in line with surrounding noise, along with VOX Capability enabling voice activated transmission.

Unlimited connectivity, versatile by design

Along with uncompromised audio quality, it delivers versatile connectivity to personnel in the field, connecting with INVISIO control units as well as the specially designed and ultra-light Push-to-Talk P30. The P30 adds flexibility for the wearer, as it can be mounted in a left, right and center orientation. Additionally, two P30s can be connected simultaneously, providing the user with a very flexible dual-radio setup.

The headset can also be connected directly to digital devices such as smartphones and laptops, offering rich audio sound and power from these devices.

The T30 offers the capability of connecting external microphones through its U-173 plug, allowing easy integration with equipment such as gas masks. Automatic smart detection ensures the external microphone gets priority over the boom microphone. The Redundancy Tx feature will allow voice pick-up from the hear-through microphones in case the boom arm is lost or defective.

Versatile power modes mean the T30 can operate as a stand-alone headset, powered by a single AA battery (up to 110 hours battery life), or draw power from a connected device. The headset transitions between power modes without operational disruptions.

Users can easily swap between wearing styles in two minutes, without using tools, providing added versatility. On top of this, the headset is water and humidity repellent, submersible down to two meters for two hours.

Jonathan Wassberg, Product Manager of Headsets at INVISIO, said: “The T30 is a groundbreaking addition to our tactical communications systems and really does offer something we haven’t seen before – a stand-alone headset that eliminates the need to change headsets in different scenarios, offering unlimited versatility with zero compromise to audio quality, hearing protection and situational awareness.

“From versatile connectivity, design, and power modes to unrivalled audio adaptability, hearing protection and situational awareness, this is the culmination of INVISIO’s years of experience in this field, and answers the needs of personnel across the world, in an array of scenarios that has never been seen before.”

The INVISIO T30 in highlights:

• Market-leading hearing protection of 30 dB SNR / 33 dB NRS_A20
• 360-degree situational awareness with sound localization down to 9 degrees
• Headset-embedded INVISIO Audio, adaptive volume control and VOX capability
• Combined Active Noise Reduction and passive hearing protection
• Double hearing protection with optimized situational awareness
• Connection with INVISIO eco-system, 3rd party PTTs and digital devices
• Easy swap between three wearing styles in less than 2 minutes. No use of tools
• Multiple powering modes- through control units, digital devices, radios and AA batteries
• Right and left boom microphone configuration
• 2 meters for 2 hours submersibility

The product is expected to be available for shipment within the coming 6 months, subject to regions and variants.

The T30 will be presented at DSEI September 9-12 in London, booth number S13-510. Visit INVISIO there, or alternatively, visit Invisio.com or contact your local INVISIO representative.

To access high-resolution visuals, please click here.

Additional product data are available on request.

For further information, please contact:
Anita Nordhild Olsen, Director Global Marketing, INVISIO
Mobile: +45 2784 0260 | email: aon@invisio.com

Jonathan Wassberg, Product Manager Headsets, INVISIO
Mobile: +45 5372 7750 | email: jwb@invisio.com

About INVISIO
INVISIO develops and sells advanced communication systems with hearing protection that enable professionals in noisy and mission critical environments to communicate and operate effectively. The company operates under two brands, INVISIO and Racal Acoustics, combining insights in acoustics and human hearing with broad engineering knowledge in software, materials technology, and interface. Sales are via the headquarters in Copenhagen and sales offices in the USA, France, the UK, Italy, and Thailand, as well as via a global network of partners and resellers. INVISIO’s registered office is in Stockholm, Sweden, and the company’s share is listed on Nasdaq Stockholm (IVSO). Read more at www.invisio.com

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/invisio-ab/r/unlimited-versatility–zero-compromise—invisio-announces-launch-of-new-t30-headset,c4227674

The following files are available for download:

HONG KONG, Sept. 2, 2025 /PRNewswire/ — Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study evaluating ivonescimab, in combination with standard therapy, against durvalumab (PD-L1) combination therapy, for the first-line treatment of advanced biliary tract cancer (BTC) (AK112-309/HARMONi-GI1). This Phase III trial is being conducted in China.

Ivonescimab has previously shown significant positive results in the randomized, double-blind, controlled Phase III study (HARMONi-2), where it was compared head-to-head with pembrolizumab. These results led to its approval as a first-line treatment for PD-L1-positive non-small cell lung cancer (NSCLC), marking its second approved indication. In addition, the Phase III trial of ivonescimab in combination with chemotherapy compared to tislelizumab combined with chemotherapy as a first-line treatment for squamous NSCLC, also delivered significant positive outcomes. These results highlight ivonescimab’s strong clinical breakthroughs. Whether compared to PD-1 monotherapy, PD-1 plus chemotherapy (current standard therapies for various cancers), or VEGF-related treatments, ivonescimab has consistently demonstrated its ability to drive clinical innovation.

Ivonescimab continues to validate its clinically meaningful profile and potential with a strategically expanded development program targeting key immuno-oncology settings:

Phase III trials for Lung cancer (8 registrational/Phase III trials, 4 already met primary endpoints):

• First-line NSCLC, squamous and non-squamous (versus pembrolizumab + chemotherapy; global trial)
• First-line squamous NSCLC (versus tislelizumab + chemotherapy)
• NSCLC after progression on EGFR-TKI therapy (HARMONi-A and HARMONi studies)
• First-line PD-L1-positive NSCLC (versus pembrolizumab monotherapy)
• First-line PD-L1-high expressing NSCLC (versus pembrolizumab)
• IO-resistant NSCLC
• Consolidation therapy for limited-stage small cell lung cancer (LS-SCLC) without progression after concurrent chemoradiotherapy (cCRT)

Phase III trials for core immuno-oncology indications (first-line therapy ):

• First-line biliary tract cancer (versus durvalumab + chemotherapy)
• First-line PD-L1-positive head and neck squamous cell carcinoma (HNSCC) in combination with ligufalimab (anti-CD47) versus pembrolizumab

Phase III trials for cold tumors and more:

• First-line triple-negative breast cancer (TNBC)
• First-line MSS/pMMR colorectal cancer (representing about 95% of CRC cases)
• First-line pancreatic cancer
• Additional global Phase III trials are in advanced stages of planning

An extensive clinical foundation includes over 20 Phase II studies across more than 10 additional tumor types, generating compelling efficacy and safety data that enable rapid transition to further registrational studies worldwide.

Ivonescimab uniquely targets both PD-1 and VEGF, producing a synergistic anti-tumor effect. This dual mechanism not only combines the benefits of PD-1 and VEGF inhibition but also overcomes the efficacy and safety limitations of each target alone, resulting in pronounced clinical benefits. These advantages have been confirmed across multiple Phase III trials and real-world use, rapidly establishing ivonescimab as a next-generation leader in immunotherapy and anti-angiogenic therapy.

For context, pembrolizumab (anti-PD-1) is approved for over 40 oncology indications, and bevacizumab (anti-VEGF) for more than 10. Akeso is implementing a dual-path strategy to maximize the value of ivonescimab worldwide: accelerating domestic commercialization and label expansion in China, while simultaneously advancing global development in partnership with Summit Therapeutics.

Forward-Looking Statement of Akeso, Inc.
This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.